Past Issues
See what you've been missing. Browse every issue of our free, daily briefing.
A $10M drug just turned a tiny biotech into a $6B cancer player
A Minnesota clinical-stage biotech bought a shelved Pfizer drug for pocket change in 2021. Five years later, it just got FDA approval, the stock is up roughly 600%, and the acquisition rumors are already writing themselves. Meanwhile, Biogen is betting billions on an Alzheimer's drug that technically failed its trial, and the FDA just published a literal rulebook for running clinical trials on psychedelics.
Roche just knocked out both KRAS rivals in a single Phase 3 trial
Roche's divarasib beat Amgen's sotorasib and BMS's adagrasib head-to-head in lung cancer, hitting both survival endpoints in what might be the most decisive showdown in oncology this year. Meanwhile, the FDA paused drug rejection letters after a citizen petition, China's drug deals surged, and a hair-loss drug rose from the dead.
A CRISPR cure now works on 2-year-olds. The catch: $2.2 million.
The FDA just cleared a gene therapy that could cure sickle cell disease before a toddler starts kindergarten, but the price tag and chemo conditioning make "who actually gets this" a harder question than "does it work." Meanwhile, the agency is simultaneously making it easier to build drugs for one patient and harder to predict whether it'll approve anything at all.
Uncle Sam bets $160M that gene editing can work like a software update
The federal government just launched its most ambitious bet yet on turning bespoke gene-editing therapies into something scalable, affordable, and real. Meanwhile, an Ebola strain nobody has a vaccine for just infected an American doctor, AstraZeneca's gene-silencing drug aced every biological test and still failed, and the GLP-1 price war is getting ruthless.
Pharma giants just caved on drug pricing. Here's what they actually agreed to.
The White House threatened tariffs on imported drugs and some of the world's biggest pharma companies said "fine, we'll cut prices." But the fine print tells a very different story than the headlines. Meanwhile, a cancer that kills most patients within a year just got some genuinely good news.
Pills just got a 100% tariff. The escape hatches are wild.
The Trump administration dropped the biggest tariff in pharmaceutical history: 100% on imported brand-name drugs. But the real story isn't the sticker shock; it's the tiered system of deal-making that could reshape where, how, and at what price every major drug company does business. Plus, the world's best-selling drug just met its first copycat with Phase 3 data to back it up.
The $459M drug whose foundational study just got erased from history
A blockbuster vasculitis drug just lost the paper that got it approved, GSK walked away from $700 million in Alzheimer's wreckage, and a gene-editing patent fight redrew the CRISPR map. It's a big day for uncomfortable truths in biotech.
Intellia just paused two CRISPR trials. The one-shot cure era has a problem.
A life-threatening liver toxicity case forced clinical holds on two of the most advanced in vivo CRISPR programs ever run, and the ripple effects go far beyond one company. Meanwhile, a kidney disease that had zero treatments three years ago now has its latest approval, Novo Nordisk and Hims went from courtroom enemies to business partners, and the FDA is losing staff faster than it can review drugs.
Vertex just dropped $10B on a body part nobody talks about
Vertex paid a 102% premium to buy its way into endocrinology, Gilead and Novartis went on dueling ADC shopping sprees totaling $6.5 billion, and Sarepta's flagship gene therapy got the FDA's scariest label. It's a reshuffling kind of week in biotech.
An $8 curtain, a rented lab corner, and a $2.3B Regeneron deal
Regeneron wrote a $2.3 billion check for a company that once protected its equipment with a floral curtain from a safety shower. Meanwhile, Roche just challenged two KRAS rivals to a fight and walked away with both belts. It's that kind of week.
Tepezza's $1.9B monopoly just got its first real competitor
A six-year stranglehold on thyroid eye disease treatment officially cracked open this week, and the ripple effects will reshape a nearly $2 billion market. Meanwhile, Anthropic wants to discover drugs, Roche is picking a fight with Illumina, and a CAR-T breakthrough might finally solve the solid-tumor problem.
Roche just beat both KRAS kings in the first-ever head-to-head lung cancer trial
Roche ran something nobody had tried before: a Phase 3 trial pitting its next-gen KRAS inhibitor directly against both approved rivals. It won on the two endpoints that matter most. Meanwhile, the FDA is about to let a panel of peptide sellers vote on whether their own products should be legal, and two of Wall Street's biggest names just wrote a billion-dollar check to a single biotech.
Medicare will now pay for weight-loss drugs at $50/month. Here's the catch.
Medicare just blew past a 23-year ban on covering weight-loss drugs, launching a pilot that gives seniors Wegovy and Zepbound for $50 a month. Meanwhile, the FDA had one of its busiest weeks in memory: the first oral carbapenem, gene therapy for toddlers, and a cell therapy that could reinvent bone marrow transplants. Let's get into it.
China just approved a cancer therapy that was never supposed to work
A solid tumor just got treated with CAR-T cell therapy for the first time in history, and the approval didn't come from the FDA. Meanwhile, Europe pulled the plug on an Amgen drug over fabricated trial data, Congress is investigating Big Pharma's Chinese lab work, and the FDA is trying to rebuild itself after gutting its own workforce.
9 FDA panelists, 0 objections: mRNA's flu shot moment just arrived
An FDA panel just gave Moderna's flu vaccine a perfect score, and the backstory involves a rejected application, a political firestorm, and a dramatic reversal. Meanwhile, a biotech nobody heard of just shattered the biggest biotech IPO record, and someone wrote an $11.3 billion check for the picks and shovels of cell therapy.
Novo's next-gen obesity drug just lost to Zepbound. The stock cratered 15%.
Novo Nordisk bet its future on CagriSema beating Zepbound in a head-to-head trial. It didn't even come close to a tie. Meanwhile, billion-dollar deals are reshaping prostate cancer and blood cancer, Sarepta is fighting for survival, and Lilly is quietly winning a price war.
The first China-born anesthetic just cleared the FDA. Operating rooms will never be the same.
A Chinese drugmaker just did something no one in the industry expected: got the FDA to approve an original anesthetic for American operating rooms. Meanwhile, Biogen spent $5.6 billion on Apellis and immediately torched most of the science. It's a day of firsts, farewells, and some truly creative accounting.
The FDA approved a thyroid eye drug 4 days early. Analysts say it's still underpriced.
A rare early FDA approval, the first-ever muscle gain in a muscular dystrophy trial, and a $5.6 billion acquisition that got stripped for parts before the ink dried. Today's issue covers a biotech industry that's simultaneously building breakthroughs and dismantling them.
A daily pill just doubled survival in pancreatic cancer. ASCO gave it 42 seconds.
An ASCO audience stood and cheered for 42 straight seconds after seeing a single survival curve from a pancreatic cancer trial. Meanwhile, the White House is using tariff threats to rewrite drug pricing, and Gilead can't stop shopping: $5 billion for a German ADC startup, $45 million for a drug that hasn't touched a patient.
Merck KGaA just spent $11B on a company most people have never heard of
A quiet arms race in lab tools just got loud, a single CRISPR injection is silencing a disease for good, and pig kidneys keep getting closer to solving the organ crisis. Today's issue is stacked with deals, data, and a few FDA moves that could reshape how medicine gets made, tested, and delivered.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.